HUMACYTE INC. - COMMO

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries

21 июн 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)

08 июн 2022 08:00:01 Источник Nasdaq GlobeNewswire

Humacyte to Present at the H.C. Wainwright Global Investment Conference

16 май 2022 08:00:02 Источник Nasdaq GlobeNewswire

Humacyte First Quarter 2022 Financial Results and Business Update

13 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

Humacyte to Provide Human Acellular Vessels™ (HAVs™) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

09 май 2022 08:00:02 Источник Nasdaq GlobeNewswire

Humacyte to Present First Quarter 2022 Financial Results and Provide Recent Corporate Update on May 13, 2022

06 май 2022 08:00:00 Источник Nasdaq GlobeNewswire

Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer

05 апр 2022 08:00:03 Источник Nasdaq GlobeNewswire

Humacyte Announces Date of Annual Shareholder Meeting

04 апр 2022 08:00:01 Источник Nasdaq GlobeNewswire

Humacyte Reports Fourth Quarter and Year End 2021 Financial Results and Provides Business Update

29 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Humacyte to Present Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

21 мар 2022 08:00:00 Источник Nasdaq GlobeNewswire

Humacyte to Present at Upcoming Investor Conferences in March

01 мар 2022 08:00:04 Источник Nasdaq GlobeNewswire

Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis

28 фев 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

09 фев 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios

31 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

28 янв 2022 09:15:00 Источник Nasdaq GlobeNewswire

Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society

06 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Announces Presentation of First Preclinical Results of the HAV™ in Coronary Artery Bypass Grafting at Advanced Therapies Week Conference

04 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

31 дек 2021 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft

15 дек 2021 07:30:00 Источник Nasdaq GlobeNewswire

Humacyte Presents Preclinical Results of Small-Diameter HAV™ for Use as a BTT Shunt in Pediatric Heart Disease at American Heart Association’s Scientific Sessions 2021

16 ноя 2021 07:30:00 Источник Nasdaq GlobeNewswire